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Background: In sarcoidosis, the T helper type 1 (Th1) response tends to predominate at
affected disease sites; however, whether Th1/Th2 polarization occurs in the peripheral
circulation is unknown.
Methods: Fifty-two patients with sarcoidosis and 21 healthy volunteers were investigated.
The concentrations of interferon-inducible protein 10 (IP-10)/CXCL10 and thymus- and
activation-regulated chemokine (TARC)/CCL17 in the serum, bronchoalveolar lavage fluid
(BALF) and culture supernatant were measured by an enzyme-linked immunosorbent assay.
The circulating CXCR3+ CD4+ T cells and CCR4+ CD4+ T cells were assessed by flow
cytometry.
Results: The CXCR3- or CCR4-positive ratios among CD4+ T cells were both higher in
sarcoidosis than in healthy volunteers. The serum levels of both IP-10 and TARC of the
patients with sarcoidosis were significantly higher than those of the healthy volunteers. In
patients with sarcoidosis, a larger amount of IP-10 was generated by the BALF cells,
whereas IP-10 production by peripheral blood mononuclear cells did not increase in
comparison to the control subjects. The TARC levels produced by peripheral blood
mononuclear cells of sarcoidosis patients were significantly higher than those of the
controls, while no difference existed between the 2 groups regarding TARC production by
BALF cells.Elsevier Ltd. All rights reserved.
586 5814; fax: +81 97 586 6502.
.ac.jp (S. Nureki).
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S. Nureki et al.240Conclusion: IP-10 is mainly produced at the lung and TARC in the peripheral circulation in
sarcoidosis patients. Both IP-10 and TARC cooperatively play a role in the pathogenesis of
sarcoidosis.
& 2007 Elsevier Ltd. All rights reserved.Introduction
Sarcoidosis is a multisystem inflammatory disease of
unknown etiology. It is characterized by non-caseating
epithelioid cell granulomas and the accumulation of
CD4+ T cells and macrophages at sites of inflammation.1
Previous studies have shown that a polarized T helper
type 1 (Th1) response is involved in the granuloma
formation, and Th1-associated cytokines, such as interferon
(IFN)-g and interleukin (IL)-2, play important roles in
the pathogenesis of sarcoidosis.2–4 In addition, IL-12 and
IL-18 synergistically induce increased production of IFN-g
primarily in the granulomatous tissue of sarcoidosis.5–7
Moreover, studies of intracellular cytokine expression in T
cell clones from bronchoalveolar lavage fluid (BALF) strongly
support the notion that sarcoidosis is a Th1-mediated
disease.8,9
However, the Th1/Th2 profiles associated with sarcoidosis
remain controversial. For example, Inui et al.8 reported that
the percentage of IFN-g and IL-4 producing CD4+ T cells
obtained from the peripheral blood do not significantly
differ between patients with sarcoidosis and healthy
volunteers. Whereas, Wahlstro¨m et al.9 reported that these
percentages are higher in the peripheral blood from patients
with sarcoidosis than in that from healthy volunteers. The
elevated circulating IFN-g, IL-12p40 subunit and IL-18 levels
have been observed by several groups.10,11 In addition, an
increased expression of IL-13mRNA in the peripheral mono-
nuclear cells (PBMC) of patients with sarcoidosis has also
been reported.12
Chemokines are critical elements for the selective
recruitment and activation of various leukocyte subsets
in the inflammatory process.13 IFN-inducible protein 10
(IP-10/CXCL10) is a specific ligand for the CXC chemokine
receptor (CXCR3), which is preferentially expressed on
Th1 cells.14,15 IP-10 expression is strongly induced by IFN-
g.16 At the sites of sarcoid granuloma, epithelioid cells
and CD68+ macrophages express IP-10, which contributes to
the granuloma formation by means of regulating the
migration and activation of Th1 cells toward the site of
these lesions.17 In contrast, thymus- and activation-regu-
lated chemokine (TARC) functions as a selective chemoat-
tractant for CC chemokine receptor (CCR) 4 bearing Th2
cells.18,19 TARC is therefore involved in Th2-dominant
pulmonary disorders, such as bronchial asthma and eosino-
philic pneumonia.20–22 The measurement of both Th1
chemoattractant IP-10 and Th2 chemoattractant TARC
is valuable for further understanding of the peripheral
Th1/Th2 balance in sarcoidosis.
This study investigates the IP-10 and TARC concentrations
in the BALF and serum from patients with sarcoidosis and
healthy volunteers. These data were correlated with clinical
or laboratory findings. In addition, the source of the
circulating IP-10 and TARC was determined.Materials and methods
Study population
The study group included 52 patients with sarcoidosis. The
sarcoidosis was diagnosed according to the criteria defined
in the International Statement on Sarcoidosis based on the
typical clinical features, as well as the histologic observa-
tion of non-caseating granulomas of in lung, muscle or lymph
node biopsies, and the exclusion of other diseases with
similar histologic or clinical characteristics.23 All of the
samples from the patients with sarcoidosis were obtained at
the time of diagnosis and none of the patients were being
treated with corticosteroids or other immunomodulatory
drugs at the time of sample retrieval. The control subjects
consisted of 21 healthy sex- and age-matched volunteers.
None of the healthy volunteers had a history of respiratory
disease. In addition, none of study subjects had a history of
allergic diseases.
Bronchoalveolar lavage
Bronchoalveolar lavage was performed as previously
described after obtaining informed consent.22 The
BAL procedure in healthy volunteers was approved by the
ethics committee of Oita University Faculty of Medicine.
Bronchoalveolar lavage was performed by injecting
150ml of saline into the middle lobe or left lingula. The
cells were counted in a hemocytometer. A 100-ml aliquot
of cells (1 106/ml) was cytocentrifuged (Cytospin,
Shandon Southern, Runcorn, UK) and air dried to obtain
differential cell counts after staining with May-Gru¨nwald-
Giemsa staining.
Flow cytometry
After lysis of the red blood cells, peripheral blood
leukocytes were incubated for 20min at 4 1C in the dark
with the following directly conjugated anti-cell-surface
marker and anti-chemokine receptor antibodies: fluorescein
isothiocyanate-conjugated anti-CD4 monoclonal antibody
(mAb) (eBiosciences Inc, San Diego, CA) and either
phycoerythrin-conjugated anti-CXCR3mAb (R & D Systems
Inc., Minneapolis, MN) or phycoerythrin-conjugated anti-
CCR4mAb (Becton Dickinson, Mountain View, CA). The cells
were washed twice, fixed in 0.2% paraformaldehyde and
analyzed in a flowcytometer (FACScalibur, Becton Dickinson)
within 24 h. The lymphocytes were easily distinguished
based on the forward and side scatters, and were isolated
by gating. The frequency of CXCR3 or CCR4+ cells was
assessed by gating for CD4+ cells. Isotype-matched negative
control antibodies (eBiosciences Inc, San Diego, CA) belong-
ing to the same immunoglobulin subclass as mAbs against
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used for setting positive thresholds. To determine the
phenotype of the lymphocytes in BALF, flow cytometry was
performed using the direct immunofluorescence method
with fluorescein isothiocyanate-conjugated anti-CD2, CD4,
and CD8mAbs. The cell-free supernatants were stored at
80 1C until further analysis.Cell culture of peripheral blood mononuclear cells
and adherence-purified BALF cells
PBMC were isolated from the blood using Ficoll-Hypaque
(Pharmacia-Biotech, Uppsala, Sweden) gradient centrifuga-
tion. The cells were washed 3 times with sterile saline and
suspended in RPMI 1640 medium containing 2mM L-gluta-
mine, 100U/ml penicillin G, 100 g/ml streptomycin, and 10%
fetal calf serum, and incubated in cell culture dishes for
30min at 37 1C in a 5% CO2 incubator. The final PBMC
concentration was adjusted to 1 106 cells/ml and the cell
cultures were returned to the incubator. After 48 h, the
culture supernatants were collected and stored at 80 1C
until further analysis. Adherence-purified BALF cells were
cultured as previously described.22 BALF cells collected by
centrifugation were suspended in the above medium and
incubated in cell culture dishes for 30min at 37 1C in a 5%
CO2 incubator. The dishes were washed 3 times with sterile
saline to remove any non-adherent cells and the remaining
adherent cells were collected. The final concentration of
adherence-purified viable BALF cells was adjusted to
0.5 105 cells/ml. They were cultured in the above medium
for 48 h at 37 1C in a 5% CO2 incubator.Table 1 Characteristics of the study populations.
Characteristics Sarcoidosis
Number 52
Sex, female/male 34/18
Age (yr), median (min, max) 53 (21, 80)
Smoking status, cur/ex/non 16/6/30
ACE (U/ml), median (min, max) 16.6 (3.6, 54
Lysozyme (ng/ml), median (min, max) 12.2 (5.8, 46
Radiologic stages
Stage, 0/I/II/III/IV 4/28/9/8/3
Extra pulmonary disease, yes/no 36/16
BALF findings
Number 46
Smoking status, cur/ex/non 13/4/29
TCC (105/ml), median (min, max) 2.3 (0.5, 10.
AM (%), median (min, max) 76.2 (31.0, 9
Lym (%), median (min, max) 20.1 (2.7, 69
Neut (%), median (min, max) 0.5 (0.0, 60.
Eo (%), median (min, max) 0.0 (0.0, 1.0
CD4/CD8, median (min, max) 5.3 (0.7, 40.
Definition of abbreviations: NS ¼ not significant, yr ¼ years, min
smoker, non ¼ non-smoker, ACE ¼ angitensin converting enzyme, N
concentration, AM ¼ alveolar macrophage, Lym ¼ lymphocyte, Neu
groups were assessed using the Student’s t-test.Measurement of IP-10 and TARC concentrations
The chemokine concentration was measured using a
commercially available enzyme-linked immunosorbent assay
kit according to the manufacturer’s protocol (R & D Systems,
Adbington, UK). The coefficients of variation for the
chemokines assays were within 10%. The minimum detect-
able levels of IP-10 and TARC were 1.67 and 7 pg/ml,
respectively.
Statistical analysis
The results were expressed as the median and interquartile
range. A statistical analysis was performed using either the
Mann–Whitney U-test or the paired Student’s t-test. Any
correlations between the 2 groups were examined using
Spearman’s rank correlation test.
Results
Patients characteristics
For the chemokine assays, 52 patients with sarcoidosis were
examined (34 women and 18 men, 21–80 years, median 53
years). The control subjects were 21 healthy sex- and age-
matched volunteers (12 women and 9 men, 26–87 years,
median age 44 years). The characteristics of the patients
and healthy volunteers are summarized in Table 1. There
was no difference in smoking status between the sarcoidosis
and control groups. The patients were divided into groups
based on the chest radiographic stages (stage 0: n ¼ 4, stage
I: n ¼ 28, stage II: n ¼ 9, stage III: n ¼ 8, stage IV: n ¼ 3).Healthy volunteers p value
21
12/9 NS
44 (26, 87) NS
7/1/13 NS
.2) ND
.5) ND
ND
14
7/1/6 NS
2) 1.4 (0.8, 3.9) p ¼ 0.0276
6.8) 96.0 (82.9, 98.0) p ¼ 0.0001
.0) 2.3 (1.3, 9.5) Po0.0001
0) 1.0 (0.0, 2.8) NS
) 0.3 (0.0, 4.7) NS
4) 1.7 (0.2, 4.7) p ¼ 0.0080
¼ minimum, max ¼ maximum, cur ¼ current smoker, ex ¼ ex-
D ¼ not done, BALF ¼ bronchoalveolar lavage, TCC ¼ total cell
t ¼ neutrophil, Eo ¼ eosinophil. Comparisons between the two
ARTICLE IN PRESS
S. Nureki et al.242BALF analysis showed that the patients with sarcoidosis had
significant higher cell concentrations, lymphocyte percen-
tage and CD4/CD8 ratios than did the healthy volunteers.
The median value of angiotensin-converting enzyme (ACE)
and lysozyme in patients with sarcoidosis was 16.6 U/ml
(range, 3.6–54.2U/ml) and 12.2mg/ml (range, 5.8–46.5
mg/ml), respectively.
IP-10 and TARC concentrations in the serum and
BALF in patients with sarcoidosis
IP-10 and TARC concentrations were measured for
52 patients with sarcoidosis and 21 healthy volunteers
(Figure 1). The median concentration of IP-10 in the serum10
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Figure 1 (A) and (B) Concentrations of IP-10 and TARC in serum o
sarcoidosis (SAR; n ¼ 52). The Y-axis shows the log of the serum IP
represents the median value. (C) Correlation between serum IP-10
TARC ratio in the serum from patients with sarcoidosis and healthy
ratio. The short horizontal line represents the median value. (E) and
healthy volunteers (HV; n ¼ 14) and patients with sarcoidosis (SAR;
(F) concentrations. The short horizontal line represents the median
U-test. NS; not significant.from patients with sarcoidosis was 389 pg/ml (range,
74–1362 pg/ml), which was significantly higher than that
from healthy volunteers (median, 82 pg/ml, range, 36–190;
po0.0001; Figure 1A). The TARC concentrations in patients
with sarcoidosis (median, 972 pg/ml, range, 59–18228
pg/ml) were also significantly higher than those in healthy
volunteers (median, 171 pg/ml, range, 93–503 pg/ml;
po0.0001; Figure 1B). There was a significant correlation
between the serum levels of IP-10 and TARC among patients
with sarcoidosis (r ¼ 0.573, po0.0001; Figure 1C). However,
the serum IP-10/TARC ratio between the 2 groups was not
significantly different (sarcoidosis; median, 0.31, range
0.04–3.42, healthy volunteers; median, 0.44, range,
0.11–1.19 pg/ml; Figure 1D).10
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and TARC concentrations in patients with sarcoidosis. (D) IP-10/
volunteers. The Y-axis shows the log of the serum IP-10/TARC
(F) Concentrations of IP-10 and TARC in the BALF obtained from
n ¼ 46). The Y-axis shows the log of the BALF IP-10 (E) and TARC
value. Paired comparisons were evaluated using Mann–Whitney
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Figure 2 (A) and (B) Percentages of CXCR3- or CCR4-bearing cells among CD4+ T lymphocytes in the peripheral blood obtained from
healthy volunteers (HV; n ¼ 10) and patients with sarcoidosis (SAR; n ¼ 10). The Y-axis shows the log of each percentage. The short
horizontal line represents the median value. (C) CXCR3/CCR4 ratio in the CD4+ T lymphocytes population in the peripheral blood of
healthy volunteers and patients with sarcoidosis. The Y-axis shows the log of the CXCR3/CCR4 ratio. The short horizontal line
represents the median value. Paired comparisons were evaluated using the Mann–Whitney U-test.
Elevated serum TARC and IP-10 in sarcoidosis 243Both the IP-10 and TARC levels were also measured in the
BALF of 46 of the 52 patients with sarcoidosis. The BALF
from 14 healthy volunteers were used controls. Figure 1E
demonstrates that IP-10 was detected in 45 patients with
sarcoidosis and 11 controls. The concentrations of IP-10 in
the BALF from patients with sarcoidosis (median, 70 pg/ml,
range 0–300 pg/ml; po0.0001) were significantly higher
than those from the healthy volunteers (median, 15 pg/ml,
range 0–35 pg/ml; po0.0001). When the sarcoidosis
patients were compared, the IP-10 levels in circulation
were not significantly correlated with those in the BALF
(r ¼ 0.261, p ¼ 0.0794). Detectable levels of TARC were
found in the BALF of only 5 patients with sarcoidosis and 2
healthy volunteers (Figure 1F).CXCR3 and CCR4 expression on peripheral blood
CD4+ T cells
To determine Th1/Th2 polarization in peripheral blood in
sarcoidosis, 2-color flow cytometry was performed for 10
patients with sarcoidosis (6 women and 4 men, 33–68
years, median 55 years, current smoker/ex-smoker/non-
smoker ¼ 3/2/5) and 10 healthy volunteers (6 women and 4
men, 26–70 years, median age 51 years, current smoker/ex-
smoker/non-smoker ¼ 3/1/6) who gave informed consent
(Figure 2). There was no difference in age, sex, and smoking
status between the sarcoidosis and control groups. Based on
the chest X-ray findings, sarcoidosis patients were dividedinto stage 0 (n ¼ 2), stage I (n ¼ 5), stage II (n ¼ 3). Seven
patients had extra pulmonary disease. Data are presented
as the positive ratio of each CCR, Th1-associated CXCR3 or
Th2-associated CCR4, in CD4+ T cells. Patients with
sarcoidosis had significantly higher percentages of CXCR3+
CD4+ lymphocytes (median, 3.3%, range, 2.0–37.8%) than
did the healthy volunteers (median, 0.6%, range, 0.2–1.5%;
p ¼ 0.0002). The percentages of CCR4-positive cells among
CD4+ Tcells were significantly higher in the peripheral blood
lymphocytes (PBL) from patients with sarcoidosis (median,
3.3%, range 1.0%–37.6%) than that in PBL from healthy
volunteers (median, 1.2%, range, 0.6–3.2%; p ¼ 0.0209).
In addition, the CXCR3+/CCR4+ ratios among CD4+ T cells
were higher in PBL from the patients with sarcoidosis
(median, 1.0%, range, 0.7–2.0%) than those in the PBL from
healthy volunteers (median, 0.5%, range, 0.1–1.3%;
p ¼ 0.0121).Production of IP-10 and TARC by adherence-purified
BALF cells and PBMC from patients with sarcoidosis
and healthy volunteers
IP-10 and TARC productions were examined by measuring
the concentrations in the culture supernatant of adherence-
purified BALF cells and PBMC from 10 patients with
sarcoidosis (4 women and 6 men, 24–80 years, median 43
years, current smoker/ex-smoker/non-smoker ¼ 6/1/3)
and 10 healthy volunteers (4 women and 6 men, 26–81
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Figure 3 Production of IP-10 and TARC by adherence-purified BALF cells and peripheral blood mononuclear cells (PMBC) obtained
from healthy volunteers (HV; n ¼ 10) and patients with sarcoidosis (SAR; n ¼ 10). The values of chemokine production are presented
as chemokine concentration per cells (pg/106 cells). The short holizontal line represents the median value. Paired comparisons were
evaluated using the Mann–Whitney U-test. NS; not significant.
S. Nureki et al.244years, median 43 years, current smoker/ex-smoker/
non-smoker ¼ 4/1/5). There was no difference in age, sex,
and smoking status between the sarcoidosis and control
groups. Based on the chest X-ray findings, sarcoidosis
patients were divided into stage 0 (n ¼ 2), stage I (n ¼ 3),
stage II (n ¼ 2), and stage III (n ¼ 3). Eight patients had
extra pulmonary disease. The values of chemokine produc-
tion per cells (pg/106cells) are shown in Figure 3. IP-10 was
detected in the culture supernatant of adherence-purified
BALF cells in 9 of 10 patients with sarcoidosis, whereas, it
was undetectable in all control subjects. The IP-10 produc-
tion by adherence-purified BALF cells was significantly
higher in the patients with sarcoidosis (median, 100 pg/ml;
range, 0.0–520 pg/ml) than in the healthy volunteers
(median, 0.0 pg/ml; range, 0.0–0.0 pg/ml; Figure 3A). The
sarcoidosis group tended to have lower value of IP-10 in the
culture supernatant of PBMC compared with the control
group, although there was no statistical difference between
the 2 groups (sarcoidosis: median, 43 pg/ml; range,
5–279 pg/ml, healthy volunteer: median, 67 pg/ml; range,
38–1593 pg/ml; Figure 3B).
No difference was observed in TARC production by
adherence-purified BALF cells between patients with sarcoi-
dosis (median, 0 pg/ml; range, 0–240 pg/ml) and healthy
volunteers (median, 0.0 pg/ml; range, 0.0–1860 pg/ml;
Figure 3C). In contrast, the TARC production by PBMC from
patients with sarcoidosis (median, 34 pg/ml; range,
0.0–150 pg/ml) was significantly higher than that from
healthy volunteers (median, 0 pg/ml; range, 0.0–62 pg/ml;
Figure 3D).Discussion
This study demonstrated that circulating levels of the
Th2-chemoattractant TARC as well as the Th1-chemoattrac-
tant IP-10 were significantly elevated in patients with
sarcoidosis. It is important to note that, compared with
the healthy controls, IP-10 was predominantly generated by
the BALF cells but not by PBMC, whereas an increased TARC
production was found in the PBMC but not in BALF cells in
the patients with sarcoidosis. Previously, Th2-associated
chemokine production had not been reported in the PBMC of
the sarcoidosis patients.
BALF IP-10 levels in these patients were also considerably
higher than those in control subjects. Similarly, increased
levels of IP-10 were generated by BALF cells from patients
with sarcoidosis than in control subjects. These results were
consistent with those of Agostini et al.17, which documented
an enhanced expression of IP-10 in sarcoid tissues and
alveolar macrophages and very high levels of IP-10 in the
BALF of 24 patients with active pulmonary sarcoidosis,
compared with patients with inactive disease or control
subjects. In addition, they demonstrated a positive relation-
ship between the BALF IP-10 levels and the degree of
infiltrated CD4+ T cells expressing Th1 cytokines (IL-2 and
IFN-g) and high levels of CXCR3.17 Elevated levels of IP-10 in
the BALF of patients with sarcoidosis were also reported by
several groups.24–27 IP-10 appears to be more important in
Th1-type immune responses because its expression is
stimulated by IFN-g and inhibited by IL-4.28,29 Increased
IP-10 expression in the inflamed lung tissue associated with
ARTICLE IN PRESS
Elevated serum TARC and IP-10 in sarcoidosis 245sarcoidosis suggests its pivotal role in attracting T cells to
sites of ongoing inflammation. The present study was the
first to observe that level of IP-10 produced by PBMC from
sarcoidosis patients was comparable to that from healthy
volunteers. The correlation between IP-10 levels of serum
and BALF was not significant and circulating levels of IP-10
were not associated with the X-ray-based stage of sarcoi-
dosis, indicating that elevated levels of circulating IP-10 are
derived from not only the lungs but also extra-pulmonary
organs. In contrast to BALF IP-10, which is a marker of T cell
alveolitis,17 serum IP-10 probably reflects systemic disease
activity.
In this study, serum levels of the Th2-associated chemo-
kine TARC was significantly elevated in patients with
sarcoidosis compared with healthy volunteers. TARC is
important in initiating a Th2 response characterized by
T cell infiltration. Several studies have documented the
involvement of TARC in Th2-associated disorders, such
as bronchial asthma, eosinophilic pneumonia and
atopic dermatitis.20–22,30,31 The expression of TARC in
Th1-mediated diseases, however, has not been well docu-
mented. Moreover, the roles of this chemokine in the
pathogenesis of sarcoidosis have not been studied. The
increased circulating TARC levels found in this study may
support the previous reports demonstrating increased
numbers of CD4+ T cells expressing the TARC receptor
CCR4 25 and the elevated IL-13 levels in serum from
sarcoidosis patients.12 The Serum TARC has recently been
associated with disease activity in bronchial asthma, atopic
dermatitis and eosinophilic pneumonia.32,33 Elevated levels
of serum TARC have also been reported as a prognostic
factor in Hodgkins disease.34 However, in contrast to these
disorders in which elevated expression of TARC is observed
in the tissue of the affected organs, TARC levels of BALF as
well as culture supernatants of BALF cells of patients with
sarcoidosis were not elevated, despite the high level of TARC
present in the peripheral blood. The PBMC from patients
with sarcoidosis secreted more TARC protein, without
cytokine stimulation than that seen in healthy volunteers.
Therefore, the elevated concentration of circulating TARC
appears to be due to increased production by the PBMC, but
not by the inflamed organs.
There is no definitive explanation for the presence of
elevated TARC levels in the associated with sarcoidosis,
which is a Th1-mediated disease. Generally, the Th1-
polarized immune response plays an important role in the
onset and development of the granulomas. And elevated
TARC levels were not observed in the lungs, which is
consistent with previous reports.21,35 This suggests that
TARC is unlikely to locally contribute to T cell alveolitis or
granuloma formation. It is possible that circulating TARC
may play a role in compensation for the Th1-polarized
response, at the peripheral blood level. This is supported by
the observation that the serum TARC levels were correlated
with the serum IP-10 levels in the same samples from
sarcoidosis patients. Elevated TARC production by the PBMC
may lead to normalization of the Th1/Th2 imbalance in
circulation and thus contribute to the pathogenesis of
sarcoidosis.
One other explanation for the elevated TARC in peripheral
blood is that sarcoidosis leads to a general activation of T
cells, similar to its effect on B cells. This general activationis non-specific and therefore both Th-1 and Th-2 chemokines
are increased. It is only in localized areas that the
differentiation occurs.
Recently, Katchar et al.36 investigated the distribution of
CXCR3- or CCR4-bearing CD4+ cells in the BALF and
peripheral blood of sarcoidosis patients. They showed that
CXCR3 was expressed on the majority of the BALF CD4+ T
cells whereas one-third population of PBL CD4+ T cells
expressed CXCR3. However, there were significantly lower
numbers of BALF CD4+ Tcells that expressed CCR4 compared
with PBL CD4+ T cells.36 It is possible that Th2 cell-
predominance exists at the PBL level in sarcoidosis. The
present study compared the proportion of CCR4+ cells as
well as CXCR3+ cells in the CD4+ T cell population in
peripheral blood, demonstrating higher proportion of both
cell types in patients with sarcoidosis than in healthy
volunteers. As a result, the CXCR3/CCR4 ratio in the CD4+
cells of sarcoidosis patients was slightly higher than that in
the controls, indicating the presence of Th1-predominance
in circulation. This might result from the contribution
of other CXCR3 ligands, such as monokines induced by
IFN-g/CXCL9 37 and IFN-g inducible T cell a-chemoattrac-
tants/CXCL11.38
Although Th1- and Th2-directed chemokines are involved
in the pathogenesis of the specific disorders, Th1/Th2
chemokine profiles in serum and tissue samples are more
complicated. For example, IP-10 as well as TARC is highly
expressed in bronchial biopsy specimens in bronchial asthma
39 and both IP-10 and TARC levels are elevated in the
circulation of patients with systemic sclerosis, though, both
are Th2-predominant diseases.40 In sarcoidosis, elevated
levels of both IP-10 and TARC in association with elevated
numbers of Th1 and Th2 cells in the peripheral blood also
seem to reflect the systemic nature of this disease.
In conclusion, patients with sarcoidosis had extremely
high concentrations of TARC as well as IP-10 in their serum.
This study suggests that IP-10 is mainly produced at the lung
and TARC is produced in the peripheral circulation in
sarcoidosis. Both IP-10 and TARC generated at these
different sites cooperatively play a role in the pathogenesis
of sarcoidosis. Further studies to elucidate the regulatory
mechanisms of Th1/Th2 balance in association with chemo-
kine expression in the peripheral blood circulation are thus
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